Improved Detection of Recurrent Bladder Cancer Using the Bard BTA stat Test

Sarosdy, Michael F.; Hudson, M’Liss A.; Ellis, William; Soloway, Mark S.; White, Ralph deVere; Sheinfeld, Joel; Jarowenko, Mark V.; Schellhammer, Paul F.; Schervish, Edward; Patel, Jaina; Chodak, G.W.; Lamm, Donald L.; Johnson, Rylee; Henderson, Maureen; Adams, George W.; Blumenstein, Brent A.; Thoelke, K.R.; Pfalzgraf, Robert; Murchison, H.A.; Brunelle, Serge

doi:10.1016/s0022-5347(01)63878-3

Cited by 36 publications

(55 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For both noninvasive (Tis, Ta, T1) and invasive (T2-T4) tumors, the BTA-Stat test is variously reported to have sensitivities within the range 50%-83% (234 -238 ) and specificities within the range 60%-92% (236,239,240 ). Falsepositive test results are reported to occur in some patients after trauma and in patients with infection of the bladder or urinary tract, nephritis, urinary calculi, or benign prostatic hyperplasia (241 ).…”

Section: Bta-stat and Trak Tests For Complement Factor H And Related mentioning

confidence: 99%

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Liver, Bladder, Cervical, and Gastric Cancers

et al. 2010

View full text Add to dashboard Cite

Background: Updated National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for the use of tumor markers in the clinic have been developed. Methods: Published reports relevant to use of tumor markers for 4 cancer sites—liver, bladder, cervical, and gastric—were critically reviewed. Results: α-Fetoprotein (AFP) may be used in conjunction with abdominal ultrasound for early detection of hepatocellular carcinoma (HCC) in patients with chronic hepatitis or cirrhosis associated with hepatitis B or C virus infection. AFP concentrations >200 μg/L in cirrhotic patients with typical hypervascular lesions >2 cm in size are consistent with HCC. After a diagnosis of HCC, posttreatment monitoring with AFP is recommended as an adjunct to imaging, especially in the absence of measurable disease. Although several urine markers have been proposed for bladder cancer, none at present can replace routine cystoscopy and cytology in the management of patients with this malignancy. Some may, however, be used as complementary adjuncts to direct more effective use of clinical procedures. Although carcinoembryonic antigen and CA 19-9 have been proposed for use gastric cancer and squamous cell carcinoma antigen for use in cervical cancer, none of these markers can currently be recommended for routine clinical use. Conclusions: Implementation of these recommendations should encourage optimal use of tumor markers for patients with liver, bladder, cervical, or gastric cancers.

show abstract

Section: Bta-stat and Trak Tests For Complement Factor H And Related mentioning

confidence: 99%

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Liver, Bladder, Cervical, and Gastric Cancers

et al. 2010

View full text Add to dashboard Cite

show abstract

“…The bladder tumor antigen, 4 the bladder tumor antigen stat, 5 the fibrinogen/fibrin degradation products, 6 and the nuclear matrix protein-22 tests, 3,7 have been approved by the Food and Drug Administration to be used in conjunction with cystoscopy. Additional molecular assays currently being evaluated for their diagnostic/prognostic utility 2,3,8,9 are the Telomerase, 10 Immunocyt, 11 and hyaluronic acid/hyaluronidase 12,13 tests, microsatellite analysis, 14 as well as assays detecting blood group antigens, 15 carcinoembryonic antigen, 16 p53 and retinoblastoma proteins, 3 E cadherin, 17,18 and various growth factors.…”

mentioning

confidence: 99%

Development of a Novel Proteomic Approach for the Detection of Transitional Cell Carcinoma of the Bladder in Urine

Vlahou

Schellhammer

Mendrinos

et al. 2001

The American Journal of Pathology

383

243

View full text Add to dashboard Cite

Development of noninvasive methods for the diagnosis of transitional cell carcinoma (TCC) of the bladder remains a challenge. A ProteinChip technology (sur-faceBladder cancer is the second most common genitourinary malignancy accounting for ϳ5% of all newly diagnosed cancers in the United States. 1 More than 90% are of the transitional cell carcinoma (TCC) histology. 2 At present, the most reliable way of diagnosis and surveillance of TCC is by cystoscopic examination and bladder biopsy for histological confirmation. The invasive and labor-intensive nature of this procedure presents a challenge to develop better, less costly, and noninvasive diagnostic tools. Urine cytology has for many years been the gold standard of the noninvasive approaches. It has high specificity and provides the advantage over biopsy of screening the entire urothelium. 2,3 However, its high false-negative rate, particularly for low-grade tumors, has limited its use as an adjunct to cystoscopy.Many noninvasive molecular diagnostic tests have been developed based on an ever-increasing knowledge about the molecular alterations associated with bladder cancer pathogenesis. The bladder tumor antigen, 4 the bladder tumor antigen stat, 5 the fibrinogen/fibrin degradation products, 6 and the nuclear matrix protein-22 tests, 3,7 have been approved by the Food and Drug Administration to be used in conjunction with cystoscopy. Additional molecular assays currently being evaluated for their diagnostic/prognostic utility 2,3,8,9 are the Telomerase, 10

show abstract

“…Although new tests for tumor antigens in blood or urine have been developed, their accuracy and sensitivity is far from ideal (Sarosdy et al, 1997;Serretta et al, 1998;Wiener et al, 1998;Boman et al, 2002). Urine usually contains cells with oncogene mutations that are characteristic of the related tumor types.…”

Section: Discussionmentioning

confidence: 99%

Ras Oncogene Mutations in Urine Sediments of Patients with Bladder Cancer

Buyru¹,

Tigli²,

Özcan³

et al. 2003

BMB Reports

View full text Add to dashboard Cite

Early detection of bladder cancer is particularly important since it dramatically affects the survival rates. However, neither urinary cytology nor tumor markers that are currently used are sensitive enough for the early detection of bladder cancer or recurrent disease. The ras genes are frequently mutated in cancer. In this study, we investigated the diagnostic potential of ras mutation analysis in urinary sediments of patients with bladder cancer using a singlestrand conformation polymorphism analysis and polymerase chain reaction. Mutation in codon 12 of the Hras gene was observed in 39% of the patients. Our results indicate that this approach may significantly improve diagnostic sensitivity in detecting bladder tumors.

show abstract

Improved Detection of Recurrent Bladder Cancer Using the Bard BTA stat Test

Cited by 36 publications

References 0 publications

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Liver, Bladder, Cervical, and Gastric Cancers

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Liver, Bladder, Cervical, and Gastric Cancers

Development of a Novel Proteomic Approach for the Detection of Transitional Cell Carcinoma of the Bladder in Urine

Ras Oncogene Mutations in Urine Sediments of Patients with Bladder Cancer

Contact Info

Product

Resources

About